Fig. 2From: RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter studyWaterfall plot summarizing the maximum percent change from baseline in the sum of longest diameter of target lesion and in attenuation at 2 months as measure by contrast-enhanced computed tomographyBack to article page